Circulating Biomarkers May Predict Who Will Have a Stroke
By LabMedica International staff writers Posted on 07 Sep 2016 |
Image: Ischemic stroke: The culprit is a blood clot that obstructs a blood vessel inside the brain. The clot may develop on the spot or travel through the blood from elsewhere in the body (Photo courtesy of Dr. James Beckerman, MD, FACC).
People with high levels of four biomarkers in the blood may be more likely to develop an ischemic stroke (IIS) than people with low levels of the biomarkers.
Adding these four biomarkers to an existing method of predicting a person's stroke risk based on factors such as age, sex, cholesterol and blood pressure, called the Framingham Stroke Risk Profile, improved the ability to predict who would develop a stroke.
A team of scientists led by those at McMaster University (Hamilton, ON, Canada) measured the levels of 15 biomarkers associated with inflammation in the blood of people from the Framingham Heart Study Offspring Cohort who had never had a stroke. The 3,224 participants had a mean age of 61 ± 9, with 54% of them female, at the start of the study and were followed for an average of nine year and during that time, and 98 people had a stroke.
Of the 15 biomarkers, four were associated with an increased risk of stroke. People with elevated homocysteine (tHcy) were 32% more likely to have a stroke. Those with high vascular endothelial growth factor (VEGF) were 25% more likely; those with high C-reactive protein (CRP) were 28% more likely; and those with high ln-tumor necrosis factor receptor 2 (TNFR2) were 33% more likely to have a stroke during the study.
Ashkan Shoamanesh, MD, the lead author of the study, said, “"Identifying people who are at risk for stroke can help us determine who would benefit most from existing or new therapies to prevent stroke. The study shows a relationship between high levels of the biomarkers and stroke; it does not establish that the high levels cause stroke.” He also noted that the biomarkers were measured only once and the investigators did not account for infections, chronic diseases or other conditions that could have affected the results. The study was published on August 24, 2016, in the journal Neurology.
Related Links:
McMaster University
Adding these four biomarkers to an existing method of predicting a person's stroke risk based on factors such as age, sex, cholesterol and blood pressure, called the Framingham Stroke Risk Profile, improved the ability to predict who would develop a stroke.
A team of scientists led by those at McMaster University (Hamilton, ON, Canada) measured the levels of 15 biomarkers associated with inflammation in the blood of people from the Framingham Heart Study Offspring Cohort who had never had a stroke. The 3,224 participants had a mean age of 61 ± 9, with 54% of them female, at the start of the study and were followed for an average of nine year and during that time, and 98 people had a stroke.
Of the 15 biomarkers, four were associated with an increased risk of stroke. People with elevated homocysteine (tHcy) were 32% more likely to have a stroke. Those with high vascular endothelial growth factor (VEGF) were 25% more likely; those with high C-reactive protein (CRP) were 28% more likely; and those with high ln-tumor necrosis factor receptor 2 (TNFR2) were 33% more likely to have a stroke during the study.
Ashkan Shoamanesh, MD, the lead author of the study, said, “"Identifying people who are at risk for stroke can help us determine who would benefit most from existing or new therapies to prevent stroke. The study shows a relationship between high levels of the biomarkers and stroke; it does not establish that the high levels cause stroke.” He also noted that the biomarkers were measured only once and the investigators did not account for infections, chronic diseases or other conditions that could have affected the results. The study was published on August 24, 2016, in the journal Neurology.
Related Links:
McMaster University
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines